p16 and p15 genes are putative tumor suppressor genes located on chromosome 9p21. In acute leukemias, alterations of p16 and p15 genes have been reported to occur exclusively in lymphoid lineage. We analyzed alterations of p16 and p15 genes in 46 acute leukemias with MLL gene rearrangements by Southern blot analysis, and investigated the association with clinical characteristics. We identified homozygous deletion of p16 and p15 genes in five (19%) of 27 acute lymphoblastic leukemias (ALLs) and in two (11%) of 19 acute myeloid leukemias (AMLs). Patients with homozygous deletion of p16 and p15 genes showed higher average leukocyte counts (343 × 10 9 /l vs 271 × 10 9 /l) and lower estimated 2-year survival rates than those with normal p16 and p15 genes (14.3 vs 30.7%), although the differences were not statistically significant. In addition, we investigated mutation of p16 gene by polymerase chain reaction single strand conformation polymorphism (PCR-SSCP) in 31 patients, but no mutation was found in the patients tested. Our results suggest that alterations of p16 and p15 genes are involved in a subset of acute leukemias with MLL gene rearrangement not only of lymphoid but also of myeloid phenotype. Homozygous deletion of p16 and p15 genes may be a possible adverse prognostic factor, although further analysis would be needed to confirm it.
Introduction
Several lines of evidence have pointed to chromosome 9p21 as the site of important tumor suppressor genes. [1] [2] [3] The p16 gene (also referred to as MTS1, INK4A, CDK4I or CDKN2) and p15 gene (also referred to as MTS2 or INK4B), which share extensive nucleotide sequence homology and are closely linked on 9p21, have been suggested to be new tumor suppressor genes by several investigators. The proteins encoded by p16 and p15 are key factors in the negative control of cell proliferation in that they inhibit the activity of two cyclindependent kinases (CDKs), CDK4 and CDK6. [4] [5] [6] [7] These biological properties of p16 and p15 as negative regulators of cell proliferation suggest that p16 and/or p15 genes are candidate tumor suppressor genes on 9p21. Indeed, it has been demonstrated that p16 and p15 genes are frequently deleted in many tumor cell lines and in some primary tumors. 5, 6, [8] [9] [10] In hematological malignancies, homozygous deletion of p16 and p15 genes is frequently found exclusively in malignancies with lymphoid lineage. Myeloid leukemias rarely show the aberrations of p16 or p15 gene. 11, 12 The reason for the prevalence of p16 and p15 gene alterations in the lymphoid lineage is unknown.
MLL gene located on chromosome 11q23 is often involved in translocation found in childhood acute leukemias. The usual consequence of 11q23 translocation is the fusion of Nterminal sequences of the MLL gene to a wide variety of partners producing chimeric products with putative transforming activities. 13, 14 Cases of childhood acute leukemia with rearrangements of this gene are generally characterized by young age, high white blood cell (WBC) count, organomegaly, central nervous system involvement, and poor prognosis. 15 The lineage of leukemia with MLL gene rearrangements varies according to its type of translocation. For example, t(4;11) is restricted to lymphoid phenotype, whereas t(9;11) is specifically identified in acute myeloid leukemia (AML), and t(11;19) is found both in ALL and AML. 13, 16 In addition, immunophenotyping of leukemic blasts of ALL with MLL gene rearrangement often demonstrates premature or mixed lineage characteristics -that is, positive for CD15 and negative for CD10. 17 These observations suggest that MLL gene rearrangement may affect a pluripotent hematological progenitor cell that is capable of either myeloid or lymphoid differentiation. Therefore, the analysis of p16 and p15 gene alterations in leukemia with MLL gene rearrangements may provide us with a clue for understanding the lineage specificity of p16 and p15 gene alterations. In this context, we here analyzed alterations of p16 and p15 genes in acute leukemias with MLL gene rearrangements using Southern blot analysis and polymerase chain reaction single strand conformation polymorphism (PCR-SSCP).
Materials and methods

Patients' samples
Bone marrow or peripheral blood samples of 66 patients with acute leukemias suspected of having MLL gene rearrangements were collected from several institutes after informed consent was obtained. The samples collected were either infantile leukemias, treatment-related leukemias secondary to chemotherapy, or those demonstrating translocation involving 11q23 by chromosomal analysis. As a result of Southern blot analysis of MLL gene rearrangement, 18 20 samples were excluded from the following analysis because of the lack of MLL gene rearrangement. Of the 46 samples with MLL gene rearrangements, 39 were from patients with de novo leukemias, and seven were from secondary leukemia patients who had been treated with anticancer agents. All the samples were collected at first diagnosis of the leukemia, and the proportion of leukemic cells exceeded 70%. Mononuclear cells were separated on Ficoll-Hypaque density gradient from the samples.
Southern blot analysis
Southern blot analysis of MLL gene was performed as described elsewhere. 18 The probe used in Southern blot analysis of MLL gene was 0.9 kb BamHI fragment of MLL cDNA corresponding to probe x in the previous study; 19 the restriction enzymes used were BamHI, EcoRI, XbaI, and/or BglII.
Southern blot analysis of p16 gene was performed as previously described. 20, 21 The 0.5-kb EcoRI fragment containing the coding sequence of p16 cDNA was labeled with ␣-32 PdCTP by the random priming method and used as the probe. 6 This probe cross-hybridizes to p15 gene which shares 80% sequence homology with p16 gene. Hybridization of 32 P-labeled p16 cDNA probe to normal genomic DNA digested by BamHI showed a 21-kb band containing the exons 1 and 2 of p16 gene and 5.8-kb band containing exon 2 of p15 gene. A human c-sis exon 6 probe obtained from Oncogene Science (Manhasset, NY, USA) was co-hybridized to confirm the integrity of the sample DNA. We judged the cases with no band or faintly visible 21-kb band compared to the control c-sis band as having homozygous deletion of p16 ( Figure 1 ).
PCR-SSCP and direct sequencing
PCR-SSCP analysis and direct sequencing of genomic p16 gene was performed as previously described. 20, 21 Briefly, high molecular weight DNA from samples was subjected for PCR and labeled by 32 P. Exon 1 was amplified as one fragment while exon 2 was split into two fragments 2a and 2b for amplification. The sequences of primers used and PCR parameters were the same as our previous reports. 20 The amplified DNA was denatured and fractionated by acrylamide-gel electrophoresis. The abnormally migrated band was cut out and immersed in water. DNA fragment was amplified by PCR and sequenced by the dideoxy chain termination method. Samples exhibiting band shifts were reassayed using separate PCR products to verify that the shifts were not due to Taq-induced error.
Figure 1
Southern blot analysis of p16 gene deletions in acute leukemias with MLL gene rearrangements. DNAs of leukemic cells were digested with BamHI and were hybridized by p16 cDNA probe. 21-kb band and 5.8-kb band show genomic DNA fragment containing exons 1 and 2 of p16 gene and exon 2 of p15 gene, respectively. A human c-sis probe was cohybridized as an internal control and is shown as a band at 1.8 kb. Lane 1 is normal peripheral blood as a control. p16 and p15 genes were homozygously deleted in lanes 5 (AML) and 7 (ALL).
Cytogenetic studies and immunophenotyping
The chromosomes of bone marrow or peripheral blood samples were analyzed by the regular trypsin-Giemsa-or Qbanding method as described previously. 22, 23 Cell surface antigens were detected by a standard indirect immunofluorescence assay with the use of monoclonal antibodies. 24 
Results
Patients' clinical data
Patients were 24 boys and 22 girls, with ages ranging from 0 day to 24 years old, and 26 patients were under 1 year old. Twenty-seven patients were diagnosed as ALL, and 19 patients as AML (one M1, two M2, two M4 and 14 M5 patients) based on the criteria of the French-American-British (FAB) classification. Initial WBC counts ranged from 4.4 to 1300 × 10 9 /l (median: 218 × 10 9 /l). Cytogenetic analysis demonstrated various types of 11q23 abnormalities, including 15 patients with t(4;11)(q21;q23), four patients with t(9;11)(p22;q23), six patients with t(11;19)(q23;p13), four patients with del(11)(q23) and nine patients with other translocations including t(1;11)(q21;q23), t(5;11)(q31;q23), t(6;11)(q27;q23), t(10;11)(p11;q23), t(11;16)(q23;p13), t(11;18)(q23;p11), t(11;22)(q23;q13), t(5;6;11)(q12;q27;q23), and t(11;15;19)(q23;q22;p13). Two patients were judged as having normal chromosome, and karyotyping was unsuccessful in the remaining six. Chromosomal 9p deletions were not detected in any cases. The summary of clinical diagnoses and chromosomal analyses were listed in Table 1 .
Homozygous deletions of p16 and p15 genes
Homozygous deletion of p16 gene was found in seven (15%) out of 46 patients with MLL gene rearrangements. These included three ALL patients with t(4;11), one AML (M5) patient with t(9;11), one AML (M4) patient with del(11)(q23), and two ALL patients with unsuccessful karyotyping ( Table 2 ). The t(9;11)-AML patient was secondary to ALL, and the remaining six were de novo leukemias. All seven patients demonstrated simultaneous p15 gene deletion. Clinical data on these seven patients are summarized in Table 3 .
The t(9;11)-AML (M5) patient was a 14-year-old boy who had been diagnosed as B-precursor ALL at the age of 10 years. He had been treated with chemotherapy including a total of 1060 mg of etoposide. Seven months after the final therapy, he developed AML (M5). WBC count at presentation was 216 × 10 9 /l, and his blasts expressed CD11b, CD13, CD14, and CD33 antigens, but not CD10 or CD19 antigen. He died within 1 month after the onset of secondary leukemia. The del(11)(q23)-AML (M4) patient was a 24-year-old-female, and her WBC count was 27 × 10 9 /l at presentation. Her leukemic blasts expressed CD13, CD15 and CD33 antigens, but not CD19 antigen. She relapsed during her course of chemotherapy and died 10 months after diagnosis.
SSCP analysis of p16 gene
Among 39 patients lacking p16 gene homozygous deletion by Southern blotting, sufficient DNA for further analysis was available in 31 patients. SSCP analysis of p16 gene was performed on these 31 patients in order to identify small mutations. Only one patient showed an abnormal shifted band of fragment 2b. Direct sequence revealed silent mutation from GGG to GGA at codon 98, and this nucleotide change was judged to be a genetic polymorphism.
Correlations between p16 and p15 genes alterations and clinical data
In order to reveal the clinical significance of p16 and p15 gene alterations in leukemias with MLL gene rearrangements, we analyzed the correlation between p16 and p15 gene alterations and clinical data ( Table 2 ). The median age of patients with p16 and p15 deletion was 24 months, which was not statistically different from that of the remaining 39 patients (9 months). The average WBC counts at presentation of the patients with or without p16 and p15 deletion were 343 × 10 9 /l vs 271 × 10 9 /l; the difference in WBC counts between the two groups was not significant by Student's t-test (P Ͼ 0.1). We also compared the clinical outcome between these two groups. Among 37 patients with normal p16 gene, 13 are alive, and seven of them have survived beyond 3 years after diagnosis. In contrast, all seven patients with p16 gene homozygous deletion died within first 3 years. The estimated 2-year overall survival rate by the Kaplan-Meier method for patients with or without p16 and p15 abnormalities was 14.3 vs 30.7%. However, the survival curve by the Kaplan-Meier method did not show a significant difference between the two groups by the log-rank test (P Ͼ 0.1).
Discussion
Recent advances in the molecular biology in human malignancies have demonstrated that the genesis and the progression of a tumor are due to the accumulation of multiple genetic alterations, including the gain of function of protooncogenes and the inactivation of the so-called tumor suppressor genes. 25, 26 In particular, increasing evidence has clearly demonstrated that cancer transformation is due to the loss of function of specific tumor suppressor genes (Rb, p53, and p16 genes) controlling the cell division cycle in many tumors. 27 Tumors with chromosomal translocation, which is considered a main genetic lesion for the tumor, are often accompanied by additional aberration of tumor suppressor gene(s). 28, 29 In our present study, a subset of acute leukemias with MLL gene rearrangement demonstrated homozygous deletion of p16 and p15 genes. Lanza et al 29 have recently reported that p53 gene mutations are frequently found in acute leukemias with MLL rearrangement. These results suggest that functional loss of tumor suppressor gene(s) can contribute to the progression of this type of leukemia.
p16 and p15 gene alterations are frequently associated with specific subtypes of hematological malignancies. Several authors have reported that p16 and p15 genes are homozygously deleted in 20-40% of B-precursor ALLs, and more frequently in T-ALLs, but rarely in AMLs. 11, [30] [31] [32] In our present study, two out of 17 AML with 11q23 rearangement showed homozygous deletion. Our two AML cases with p16 gene homozygous deletion are notable because many authors have reported complete absence of p16 deletion in AMLs. 11, 30, 31 Exceptionally, Nakamaki et al 32 reported that two of 46 AMLs showed p16 gene deletion, and that both cases expressed lymphoid antigens on leukemic blasts. AML with MLL gene rearrangement often shows co-expression of lymphoid antigens, and thus it is considered as having mixed lineage character. p16 gene deletion in AML may be found only in cases of mixed lineage or undifferentiated subtype such as AML with MLL gene rearrangement.
The reason for the prevalence of p16 and p15 gene alterations in lymphoid malignancies is unknown. The deletion of p16 and p15 genes may depend on the activity of the recombinase which is specific for rearrangement of immunoglobulin or T cell receptor of lymphocytes. Such a mechanism has been implicated in the translocation of the TAL-1 gene that is associated with T-ALL. 33, 34 Mutations of p16 gene were not found in our present series. In our previous study and those of others, p16 gene mutation is less frequent than deletion in leukemias. 20, 30 Several recent reports showed that methylation of the promoter region of the p16 gene causes the functional loss of p16 at considerable frequency in some tumors including hematological malignancies. [35] [36] [37] [38] We studied the methylation status of the p16 promoter in some cases in which sufficient DNA was available, but no case was found to be methylated in this region (data not shown). Recently Herman et al 37 have distinctly demonstrated that among 87 AML cases, only (1%) showed hypermethylation of the p16 promoter, while 71 (82%) cases had methylated p15 promoter region. In AML, inactivation of the p15 gene by hypermethylation of the p15 promoter may be more important than p16 inactivation. The contribution of p15 promoter methylation in 11q23 AML is yet to be clarified.
The clinical significance of alterations of p16 and p15 genes in leukemia is still unknown. Several studies have pointed out the association of the p16 gene homozygous deletion with adverse clinical features and poor prognosis in ALL. 12, 31 In our present study, patients with p16 and p15 deletion showed trends toward higher WBC counts at presentation and lower estimated survival rates than those without the p16 and p15 deletion. However, the trends revealed by our analysis of the role of p16 deletion on these clinical features did not reach statistical significance. Further prospective study using uniform therapy would be needed to clarify the clinical significance of the p16 and p15 gene alterations in acute leukemias with MLL gene rearrangements.
In conclusion, we found homozygous deletion of p16 and p15 genes in a subset of acute leukemias with MLL gene rearrangement not only of lymphoid but also of myeloid phenotype. The lineage specificity and clinical relevance of p16 deletion should be elucidated hereafter.
Note added in proof
After submitting this manuscript, KW Maloney and colleagues published their works on p16/p15 deletion in infantile ALLs (Leukemia 1997; 11: 979-983). Contrary to our result, they reported the entire absence of p16/p15 deletion in 44 American infantile ALLs with MLL rearrangement. Taking into account that the frequency of p16 deletion in childhood T-ALL varies between reports from different countries, an ethnic factor may explain the difference of frequency of p16 deletion in MLL-rearranged ALL in these two papers. Alternatively, patient selection in the two papers differs, in part because infant ALL is a relatively rare disease. Our study included some older patients with MLL rearrangement.
